Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FZ88E
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $40,603
Award facts
- Contract value 100% obligated
- $40,603.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $40,603.18 delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injections under a firm fixed price contract. This is a non-set-aside award utilizing a competitive procurement process. The place of performance is identified as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with a completion deadline of December 5, 2025. As a child order, this delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vendor agreement running through December 2026 that supports comprehensive pharmaceutical supply needs across military healthcare systems globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through the Defense Logistics Agency's supply chain. The company's extensive portfolio with DLA includes a wide range of pharmaceutical products spanning multiple therapeutic domains, including specialty medications, vaccines, and medical supplies for military and veteran healthcare systems. The SPE2DX indefinite delivery vehicle enables flexible procurement of essential medications and medical commodities to support Defense Health Agency operations and other federal healthcare systems. This specific delivery order for Dupixent, a prescription immunosuppressant used to treat conditions such as atopic dermatitis and eosinophilic asthma, represents routine pharmaceutical resupply under the broader prime vendor agreement established to ensure reliable availability of critical medical products for the military health system.
Quick answers
Who was awarded contract SPE2DR26FZ88E?
SPE2DR26FZ88E was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26FZ88E worth?
The government has obligated $40,603 on SPE2DR26FZ88E.
Is contract SPE2DR26FZ88E an order under another contract?
Yes. SPE2DR26FZ88E is a delivery order under SPE2DR25D2014, an indefinite delivery contract.
Was contract SPE2DR26FZ88E competed?
The extent of competition for SPE2DR26FZ88E was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award